Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
RD-129 by Nanjing IASO Biotherapeutics for Autoimmune Disorders: Likelihood of Approval
RD-129 is under clinical development by Nanjing IASO Biotherapeutics and currently in Phase I for Autoimmune Disorders. According to GlobalData,...
Data Insights
RD-129 by Nanjing IASO Biotherapeutics for Autoimmune Disorders: Likelihood of Approval
RD-129 is under clinical development by Nanjing IASO Biotherapeutics and currently in Phase I for Autoimmune Disorders. According to GlobalData,...